

## Challenges and Opportunities in Vaccines and Global Immunisation

***Helen Evans, Deputy CEO***


*CSIS conference on the strategic power of  
vaccines*

*Washington DC, 9 December 2011*



# Over 19 million children still unimmunised


Global number of under-five children unimmunised with 3 doses of DTP



\*From 2011, GAVI has 57 eligible countries.


# Taking stock: the immunisation gap

136 million surviving newborns in 2010:




# The immunisation landscape

## Synergies and shared learnings




# Pneumococcal vaccine introductions: introduced, approved and forecast



Helen Evans – CSIS Conference  
9 December 2011

# Rotavirus vaccine introductions: introduced, approved and forecast




Source: Demand forecast v 4.0

Helen Evans – CSIS Conference  
9 December 2011

# Increased competition reduces vaccine price

Number of manufacturers and price decline of pentavalent vaccine




Source: UNICEF Supply Division, 2011

Helen Evans – CSIS Conference  
9 December 2011

# Increased competition reduces vaccine price

Number of manufacturers and volume of supply of pentavalent vaccine



Source: UNICEF Supply Division, 2011

Helen Evans – CSIS Conference  
9 December 2011



# Leveraging the market:

## GAVI's Market Shaping in action 2011+

### Short Term

#### *Price decreases*

- Pentavalent price decreases to \$1.75 from \$3 two years ago
- 67% price reduction offer on rotavirus - \$2.5/dose
- 67% price reduction offer on HPV - \$5/dose

### Medium Term

#### *New entrants*

- 3 potential new entrants for rotavirus, yielding a further 40% price reduction target
- New entrants for pneumo, yielding a further price reduction of approx. 40%
- Graduating country price commitments

### Long Term

#### *Innovation*

- Foster incremental innovation for appropriate and affordable new and follow-on products
- Improvements in vaccine technology

# National leadership - Pneumococcal vaccine launch, Kenya, 14 February 2011




Photo: GAVI/2011/Riccardo Gangale



[www.gavialliance.org](http://www.gavialliance.org)

# Current cervical cancer mortality




Source: Globocan 2008, International Agency for Research on Cancer.  
Courtesy of Progress in Cervical Cancer Prevention:  
The CCA Report Card, August 2011

Helen Evans – CSIS Conference  
9 December 2011

# Introduction of HPV vaccine

Status: July 2011



Source: Courtesy of Progress in Cervical Cancer Prevention:  
The CCA Report Card, August 2011

Helen Evans – CSIS Conference  
9 December 2011